|Bid||9,951.00 x 0|
|Ask||9,953.00 x 0|
|Day's Range||9,893.00 - 10,038.00|
|52 Week Range||8,090.32 - 11,540.00|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||45.61|
|Earnings Date||Nov 10, 2022|
|Forward Dividend & Yield||2.22 (1.93%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||114.44|
Coca-Cola (KO), General Dynamics (GD), AstraZeneca (AZN), Boise Cascade (BCC), and Insperity (NSP) that offer dividend growth could be compelling picks amid market volatility.
AZN vs. LLY: Which Stock Is the Better Value Option?
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) received a notice that its partner SFJ Pharmaceuticals Group elected to transfer bentracimab rights to SFJ as PhaseBio failed to remedy its Going Concern Condition. Formerly known as PB2452, bentracimab reverses the effects of AstraZeneca Plc's (NASDAQ: AZN) blood thinner Brilinta (ticagrelor) In January 2020, PhaseBio announced a financing and co-development partnership with SFJ Pharmaceuticals. PhaseBio retains exclusive worldwide commercial rights.